Published Ahead of Print 17 October 2011. 10.1128/AAC.05348-11. 2012, 56(1):595. DOI:Antimicrob. Agents Chemother.  Soares Mendes-Giannini Regina Helena Pires, Rodrigo Lucarini and Maria Jose   orthopsilosis and C. parapsilosis Effect of Usnic Acid on Candida http://aac.asm.org/content/56/1/595 Updated information and services can be found at: These include: REFERENCES http://aac.asm.org/content/56/1/595#ref-list-1 This article cites 22 articles, 8 of which can be accessed free at: CONTENT ALERTS more»articles cite this article), Receive: RSS Feeds, eTOCs, free email alerts (when new http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: on S eptem ber 13, 2013 by U N E S P - U niversidade E stadual P aulista http://aac.asm .org/ D ow nloaded from http://aac.asm.org/cgi/alerts http://aac.asm.org/ Effect of Usnic Acid on Candida orthopsilosis and C. parapsilosis Regina Helena Pires,a Rodrigo Lucarini,b and Maria Jose Soares Mendes-Gianninia Universidade Estadual Paulista, UNESP, Araraquara, SP, Brazil,a and Universidade de Franca, Franca, SP, Brazilb The activity of usnic acid against Candida orthopsilosis and Candida parapsilosis on planktonic and biofilm conditions was in- vestigated by using a broth microdilution and microplate methods. Potent in vitro activities against different Candida species were obtained. The metabolic activity of sessile cells of C. parapsilosis complex was reduced by 80% at four times the 80% inhibi- tory concentration. The in vitro studies support further efforts to determine whether usnic acid can be used clinically to cure patients with Candida infections. Among the Candida strains reported to cause human diseases, more than 17 different species have been identified (9, 19). Many of these species have been observed to occur in the hemo- dialysis setting and/or to exhibit innate or acquired resistance to one or more established antifungal agents (4, 12, 13, 16, 21). In addition, the use of molecular identification methods has resulted in the identification of new species within larger species complex such as Candida orthopsilosis and Candida metapsilosis within the Candida parapsilosis complex (23). In particular, the percentage of isolates of C. orthopsilosis has been much higher in the C. parapsi- losis complex isolates in Latin America (12.7%) (11). The small number of drugs available for fungal treatment encourages the search for new chemotherapeutic agents. Usnic acid (2,6-diacetyl-1,2,3,9b-tetrahydro-7,9-dihydroxy-8,9b-di- methyldibenzofuran-1,3-dione), a secondary lichen metabolite, is known to possesses antimicrobial properties in addition to an- tiviral, antiprotozoal, antiproliferative, anti-inflammatory, and analgesic activity (10). With respect to antimicrobial properties, usnic acid has activ- ity against a number of planktonic Gram-positive bacteria and also has the capacity to control biofilm formation by Staphylococ- cus aureus and Pseudomonas aeruginosa (8). Indeed, the mecha- nism of action expressed by usnic acid is still unknown. According to the same study (8), usnic acid could inhibit quorum sensing in P. aeruginosa biofilms. Usnic acid has been tested against some Candida species, but there is no published data concerning its activity against the newly described species within the C. parapsilosis complex. Thus, we tested usnic acid in both planktonic or biofilm modes of growth in C. orthopsilosis and C. parapsilosis. Six isolates of C. parapsilosis complex able to form biofilms were collected from a hemodialysis unit located in the state of São Paulo, Brazil, between March 2006 and March 2007 obtained from 110 samples of water that were selected for testing. The iden- tification of C. parapsilosis and C. orthopsilosis was confirmed by molecular methods as described previously (23). The MIC for usnic acid of planktonic C. parapsilosis complex cultures was de- termined in RPMI 1640 buffered with morpholinepropanesulfo- nic acid (MOPS) (both from Sigma Chemical Co., St. Louis, MO) using a broth microdilution method adapted from the CLSI ap- proved standard (M27-A3) (6). Briefly, the usnic acid (Sigma) was dissolved in 5% (vol/vol) in dimethyl sulfoxide (DMSO) (Sigma) that had been filter sterilized through a 0.22-�m-pore-size filter (Millipore, Billerica, MA) and added to the growth medium to obtain final concentrations ranging from 0.48 �g/ml at 1,000 �g/ ml. Yeast cells were then added to each well at the final concentra- tion of 1 � 106 cells/ml (2, 5, 15). The microtiter trays were incu- bated at 35°C for 48 h. Afterwards, IC50 and IC80 values (the lowest concentrations that inhibit 50% and 80% of the yeast growth in comparison to untreated control, respectively), were determined using a spectrophotometer at 492 nm. Controls containing anti- microbial agents in broth without fungal inocula were included. Amphotericin B (final concentration of 0.0156 to 16 �g/ml) and the C. parapsilosis ATCC 90018 strain were used as quality con- trols. After the MIC assay, minimal fungicidal concentrations (MFCs) were determined by plating 10 �l of the material in each of the clear wells onto Sabouraud dextrose agar (SDA) (Difco) plates. The MFC was defined as the lowest concentration yielding no growth following incubation at 37°C for 48 h. The MICs for sessile (biofilm) cells (SMICs) were determined by a microtiter plate assay as described previously (20). Briefly, each well on a 96-well microtiter plate was filled with 100 �l of RPMI 1640 containing 106 cells of an overnight culture. After 24 h of incubation at 37°C, the biofilms were washed three times with sterile phosphate-buffered saline (PBS) (10 mM potassium phos- phate, 0.15 M NaCl [pH 7.0]). The biofilms were exposed to 100 �l of antimicrobial agent, and the plates were incubated for 48 h at 37°C, after which the usnic acid was removed by washing each well twice with 100 �l PBS. Fungal viability was analyzed using 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) (Sigma) as described previously (17). Briefly, 200 �l prewarmed MTT solution (0.5 mg/ml) in PBS containing 0.1% glucose and 10 �l of 10 �M menadione was added to each well. The plates were incubated at 37°C for 30 min, and the MTT solution was removed. The yeast cells were washed once with PBS and resuspended in acid isopropanol (5% [vol/vol] 1 M HCl in isopropanol). Finally, the absorbance at 540 nm (A540) was measured using a microtiter plate reader (ASYS, Eugendorf, Salzburg, Austria). The BEC50 and BEC80 for Candida biofilms were defined as the lowest drug con- centration with a 50% and 80% reduction, respectively, in the Received 21 July 2011 Returned for modification 27 August 2011 Accepted 11 October 2011 Published ahead of print 17 October 2011 Address correspondence to Regina Helena Pires, rehepi@gmail.com. Copyright © 2012, American Society for Microbiology. All Rights Reserved. doi:10.1128/AAC.05348-11 0066-4804/12/$12.00 Antimicrobial Agents and Chemotherapy p. 595–597 aac.asm.org 595 on S eptem ber 13, 2013 by U N E S P - U niversidade E stadual P aulista http://aac.asm .org/ D ow nloaded from http://dx.doi.org/10.1128/AAC.05348-11 http://aac.asm.org http://aac.asm.org/ metabolic activity of the biofilms compared to controls (drug free). The minimum biofilm fungicidal concentration (MBFC) was defined as the concentration with A540 values below or equal to the background level (acid isopropanol). The antimicrobial ac- tivity of 5% (vol/vol) DMSO was also studied on a separate plate alongside the assay plate. C. albicans SC5314 was used as the bio- film control strain (20, 22). All experiments were performed in triplicate on three different days. As shown in Table 1, usnic acid exhibited an anti-Candida effect, with IC50 of 1.95 �g/ml and IC80s of 7.8 and 15.6 �g/ml. Reduction of 50% in the metabolic activities of biofilms of both C. parapsilosis strains (BEC50) was achieved at a concentration of 3.9 �g/ml; 31.2 and 62.5 �g/ml reduced the growth of the cells in 80% (BEC80) (Table 1). In contrast, the MBFCs of usnic acid were comparable to the MFCs estimated at 125 and 250 for C. orthop- silosis and C. parapsilosis, respectively (Table 1). For these envi- ronmental isolates, C. orthopsilosis was more susceptible to usnic acid than the C. parapsilosis. The MIC values for the reference strain that was used as a positive control for amphotericin B were within the established values for the CLSI M27-A3 protocol. DMSO (5% [vol/vol]), which was used as a cosolvent in the drug suspensions, did not show anticandidal activity against C. parap- silosis complex grown in suspension or as a biofilm. Based on the existing literature, usnic acid seems to be pro- duced only in lichens and appears to be effective against a wide variety of bacterial strains, and the antifungal properties previ- ously reported by Cardarelli et al. (3) were confirmed by the re- sults of this study. Because of their antimicrobial activity, usnic acid has been the target of many studies for the purpose of devel- oping phytotherapeutic options for treatment of infections (14). According to Francolini et al. (8), there was no evidence of a toxic effect of usnic acid in pharmacokinetics studies and after oral ad- ministration. According to the values of EC50, EC80, BEC50, and BEC80 ob- tained for the isolates of C. orthopsilosis and C. parapsilosis, usnic acid demonstrated potent inhibitory activity against both plank- tonic and biofilm cells (Table 1). Furthermore, Yilmaz et al. (24) showed that usnic acid with quite low MIC values (0.15 �g per disk) was effective against 107 cells/ml of Candida albicans or Can- dida glabrata. Similarly, lower MICs (ranging from 1 to 26 �g/ml) determined by the disk diffusion method have been observed against Bacillus subtilis (18). One factor that may explain our re- sults include the absence of standardized anticandidal assays for natural products. Results can be profoundly influenced by the testing method (7). Previous studies have shown that antimicro- bial activity can be more effectively evaluated in liquid media than in solid media, since in the latter, the diffusion of drug may not be appropriate (1). The results presented in this study are the first report of usnic acid showing in vitro inhibitory and fungicidal activity against environmental isolates of C. orthopsilosis and C. parapsilosis. Con- sidering also the absence of cytotoxicity and low concentrations obtained, usnic acid represents a promising area of future re- search. The mechanisms of its antifungal activity should be stud- ied in order to validate the use of usnic acid as a natural antifungal product. REFERENCES 1. Al-Hiti MM, Gilbert P. 1983. A note on inoculum reproducibility: a comparison between solid and liquid culture. J. Appl. Bacteriol. 55: 173–175. 2. Braga PC, Culici M, Alfieri M, Dal Sasso M. 2008. Thymol inhibits Candida albicans biofilm formation and mature biofilm. Int. J. Antimi- crob. Agents. 31:472– 477. 3. Cardarelli M, et al. 1997. Antimitotic effects of usnic acid on different biological systems. Cell. Mol. Life Sci. 53:667– 672. 4. Centers for Disease Control and Prevention (CDC). 2011. Vital signs: central line-associated blood stream infections–United States, 2001, 2008, and 2009. Morb. Mortal. Wkly. Rep. 60:243–248. 5. Chami N, Bennis S, Chami F, Aboussekhra A, Remmal A. 2005. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo. Oral Microbiol. Immunol. 20:106 –111. 6. Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved stan- dard CLSI document M27-A3. Clinical and Laboratory Standards Insti- tute, Wayne, PA. 7. Cos P, Vlietinck AJ, Berghe DV, Maes L. 2006. Anti-infective potential of natural products: how to develop a stronger in vitro “proof-of- concept.” J. Ethnopharmacol. 106:290 –302. 8. Francolini I, Norris P, Piozzi A, Donelli G, Stoodley P. 2004. Usnic acid, a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. Antimicrob. Agents Chemother. 48:4360 – 4365. 9. Hazen KC, Howell SA. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p 1762–1788. InMurray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (ed), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC. 10. Ingólfsdóttir K. 2002. Usnic acid. Phytochemistry 61:729 –736. 11. Lockhart SR, Messer SA, Tendolkar S, Diekema DJ. 2008. Geographic distribution and antifungal susceptibility of newly described species Can- dida orthopsilosis, in comparison to the closely related species Candida parapsilosis. J. Clin. Microbiol. 46:2659 –2664. 12. Marriott DJ, et al. 2009. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit. Care 13:R115. 13. Medrano DJA, et al. 2006. Candidemia in a Brazilian hospital: the impor- tance of Candida parapsilosis. Rev. Inst. Med. Trop. São Paulo 48:17–20. 14. Molnár K, Farkas E. 2010. Current results on biological activities of lichen secondary metabolites: a review. Z. Naturforsch C 65:157–173. 15. Nett JE, Guite KM, Ringeisen A, Holoyda KA, Andes DR. 2008. Re- duced biocide susceptibility in Candida albicans biofilms. Antimicrob. Agents Chemother. 52:3411–3413. 16. Nucci M, Queiroz-Telles F, Tobón AM, Restrepo A, Colombo AL. 2010. Epidemiology of opportunistic fungal infections in Latin America. Clin. Infect. Dis. 51:561–570. 17. Nuryastuti T, et al. 2009. Effect of cinnamon oil on icaA expression and biofilm formation by Staphylococcus epidermidis. Appl. Environ. Micro- biol. 75:6850 – 6855. 18. Paudel B, et al. 2010. Antibacterial activities of Ramalin, usnic acid and its three derivatives isolated from the Antarctic lichen Ramalina terebrata. Z. Naturforsch C. 65:34 –38. 19. Pfaller MA, et al. 2007. Results from the ARTEMIS DISK Global Anti- fungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of suscepti- bilities of Candida species and other yeast species to fluconazole and vori- conazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735–1745. 20. Pierce CG, et al. 2008. A simple and reproducible 96-well plate-based TABLE 1 Activities of usnic acid against C. orthopsilosis and C. parapsilosis isolates Candida species Antifungal activity (�g/ml)a Planktonic growth Biofilm growth IC50 IC80 MFC BEC50 BEC80 MBFC C. orthopsilosis 1.95 7.8 125 3.9 31.2 125 C. parapsilosis 1.95 15.6 250 3.9 62.5 250 a IC50 and IC80, concentration required for 50% and 80% inhibition in cell growth compared with the untreated controls, respectively; MFC, minimal fungicidal concentration; BEC50 and BEC80, 50% and 80% reduction in the metabolic activity of the biofilms compared to untreated controls, respectively; MBFC, minimum biofilm fungicidal concentration. Pires et al. 596 aac.asm.org Antimicrobial Agents and Chemotherapy on S eptem ber 13, 2013 by U N E S P - U niversidade E stadual P aulista http://aac.asm .org/ D ow nloaded from http://aac.asm.org http://aac.asm.org/ method for the formation of fungal biofilms and its application to anti- fungal susceptibility testing. Nat. Protoc. 3:1494 –1500. 21. Qureshi AL, Abid K. 2010. Frequency of catheter related infections in haemodialysed uraemic patients. J. Pak. Med. Assoc. 60:671– 675. 22. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. 2002. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing mole- cule. Appl. Environ. Microbiol. 68:5459 –5463. 23. Tavanti A, Davidson AD, Gow NA, Maiden MCJ, Odds FC. 2005. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Can- dida parapsilosis groups II and III. J. Clin. Microbiol. 43:284 –292. 24. Yilmaz M, Türk AO, Tay T, Kivanç M. 2004. The antimicrobial activity of extracts of the lichen Cladonia foliacea and its (�)-usnic acid, atranorin, and fumarprotocetraric acid constituents. Z. Natur- forsch C 59:249 –254. Usnic Acid on Candida parapsilosis Complex January 2012 Volume 56 Number 1 aac.asm.org 597 on S eptem ber 13, 2013 by U N E S P - U niversidade E stadual P aulista http://aac.asm .org/ D ow nloaded from http://aac.asm.org http://aac.asm.org/